Zenas BioPharma Presents New Obexelimab Data in IgG4-Related Disease
Phase 3 INDIGO open-label extension findings showed sustained clinical activity. Additional secondary-endpoint analyses found significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52.
Story updates
11:01:46 AM UTC
SquawkNews
Zenas BioPharma reported Phase 3 INDIGO open-label extension findings for obexelimab in IgG4-RD, including longer-term flare protection, reduced glucocorticoid toxicity in secondary analyses, and initial vaccine-response data after a treatment-free window.Material DetailsContext by AI AnalystThis e…